LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL)

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Mao, Yuan ^a   Zhang, Da Wei ^b   Zhu, Huijun ^c   Lin, Hong ^d   Xiong, Lin ^b   Cao, Qing ^b   Liu, Ying ^a   Li, Qing Dong ^a   Xu, Jia Ren ^a   Xu, Lin Feng ^b   Chen, Ren Jie ^b  

^a Jiangsu Provincial Hospital   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANTONG UNIVERSITY   (China)

^d Jiangsu Province Blood Center   (China)

Author keywords

EBV; ENKTL; LMP1; LMP2A; Prognosis; Tumor marker

Indexed keywords

EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; PARAFFIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHEMISTRY; CHI SQUARE DISTRIBUTION; EPSTEIN BARR VIRUS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; NK T CELL LYMPHOMA; PATHOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME; UPREGULATION; VIROLOGY;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VIRAL MATRIX PROTEINS;

MLCS; MLOWN;

EID: 84870902663     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-178     Document Type: Article

References (29)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification of tumours. Volume 3: pathology and genetics of tumours of haematopoietic and lymphoid tissue 2001, Lyon: IARC Press.
2. Pongpruttipan T, Kummalue T, Bedavanija A, Khuhapinant A, Ohshima K, Arakawa F, Niino D, Sukpanichnant S. Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand. Diagn Pathol 2011, 6:79. 10.1186/1746-1596-6-79, 3170575, 21867533.
3. Cao W, Liu Y, Zhang H, Wang S, Zhang L, Zhang L, Sun B. Expression of LMP-1 and cyclin D1 protein is correlated with an unfavorable prognosis in nasal type NK/T cell lymphoma. Mol Med Report 2008, 1:363-368.
4. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, Ito K, Kawa K, Oshimi K, NK-cell Tumor Study Group Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010, 21:1032-1040. 10.1093/annonc/mdp418, 19850638, NK-cell Tumor Study Group.
5. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol 2009, 27:6027-6032. 10.1200/JCO.2009.23.8592, 19884539.
6. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study JCOG0211. J Clin Oncol 2009, 27:5594-5600. 10.1200/JCO.2009.23.8295, 19805668.
7. Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Lannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G, Intergruppo Italiano Linfomi NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Ann Oncol 2006, 17:794-800. 10.1093/annonc/mdl015, 16497823, Intergruppo Italiano Linfomi.
8. Takahashi E, Ohshima K, Kimura H, Hara K, Suzuki R, Kawa K, Eimoto T, Nakamura S, NK-cell Tumor Study Group Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders. Histopathology 2011, 59:660-671. 10.1111/j.1365-2559.2011.03976.x, 22014047, NK-cell Tumor Study Group.
9. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008, 13:577-585. 10.1634/theoncologist.2008-0036, 18515742.
10. Cohen JI, Bollard CM, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma 2008, 1:27-34.
11. Kohrt H, Advani R. Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. Leuk Lymphoma 2009, 50:1773-1784. 10.3109/10428190903186502, 19883307.
12. Yang QX, Pei XJ, Tian XY, Li Y, Li Z. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature. Diagn Pathol 2012, 7:7. 10.1186/1746-1596-7-7, 3285033, 22260632.
13. Kieff ED, Rickinson AB, et al. Epstein-Barr virus and its replication. Fields virology, vol 2 2007, 2603-2654. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, Knipe DM, 5.
14. Shair KH, Bendt KM, Edwards RH, Bedford EC, Nielsen JN, Raab-Traub N. EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog 2007, 3:e166. 10.1371/journal.ppat.0030166, 2065877, 17997602.
15. Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, Wright KL, Kube D, Rowe M, Woodman CB, Murray PG. Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood 2011, 117:5907-5917. 10.1182/blood-2010-09-307710, 3293751, 21411757.
16. Chen F, Liu C, Lindvall C, Xu D, Ernberg I. Epstein-Barr virus latent membrane 2A (LMP2A) down-regulates telomerase reverse transcriptase(hTERT) in epithelial cell lines. Int J Cancer 2005, 113:284-289. 10.1002/ijc.20594, 15389515.
17. Pang MF, Lin KW, Peh SC. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) inlatency and cancer. Cell Mol Biol Lett 2009, 14:222-247. 10.2478/s11658-008-0045-2, 19082921.
18. Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007, 110:3715-3721. 10.1182/blood-2007-05-090142, 2077319, 17682125.
19. Bieging KT, Swanson-Mungerson M, Amick AC, Longnecker R. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A. Cell Cycle 2010, 9:901-908. 10.4161/cc.9.5.10840, 2855765, 20160479.
20. Portis T, Dyck P, Longnecker R. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in reed-Sternberg cells of Hodgkin lymphoma. Blood 2003, 102:4166-4178. 10.1182/blood-2003-04-1018, 12907455.
21. Liang X, Graham DK. Natural killer cell neoplasms. Cancer 2008, 112:1425-1436. 10.1002/cncr.23316, 18286525.
22. Friedrich M, Villena-Heinsen C, Reitnauer K, Schmidt W, Tilgen W, Reichrath J. Malignancies of the uterine corpus and immunoreactivity score of the DNA " mismatch-repair" enzyme human Mut-S-homologon-2. J Histochem Cytochem 1999, 47:113-118. 10.1177/002215549904700112, 9857218.
23. Mao Y, Zhang DW, Wen J, Cao Q, Chen RJ, Zhu J, Feng ZQ. A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor. Int J Mol Sci 2012, 13:2208-2218. 10.3390/ijms13022208, 3292017, 22408448.
24. Ho CH, Chen CL, Li WY, Chen CJ. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis 2009, 30:1443-1451. 10.1093/carcin/bgp135, 19483191.
25. Chen R, Zhang D, Mao Y, Zhu J, Ming H, Wen J, Ma J, Cao Q, Lin H, Tang Q, Liang J, Feng Z. A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. Mol Cancer Ther 2012, 11:594-603. 10.1158/1535-7163.MCT-11-0725, 22169768.
26. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110:2838-2845. 10.1182/blood-2007-05-091280, 2018666, 17609424.
27. Dargart JL, Fish K, Gordon LI, Longnecker R, Cen O. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res 2012, 95:49-56. 10.1016/j.antiviral.2012.05.003, 22609829.
28. Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O'Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 2010, 116:3695-3704. 10.1182/blood-2010-06-292268, 2981530, 20671118.
29. Du ZM, Kou CW, Wang HY, Huang MY, Liao DZ, Hu CF, Chen J, Yan LX, Hu LF, Ernberg I, Zeng YX, Shao JY. Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma. Head Neck 2012, 34:1456-1464. 10.1002/hed.21953, 22287277.